ABVC BioPharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ABVC BioPharma, Inc. on July 12, 2024, regarding an event that occurred on July 10, 2024. The Company is incorporated in Nevada and its common stock trades on The Nasdaq Stock Market LLC under the symbol "ABVC".
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes and Events
On July 10, 2024, the Company received a notification from the Nasdaq Listing Qualifications Staff stating that the minimum bid price per share for its common stock had been below $1.00 for 30 consecutive business days. Consequently, the Company no longer meets the minimum bid price requirements under Nasdaq Listing Rule 5550(a)(2). This notification has no immediate effect on the listing of the Company's common stock.
Outlook, Risks, and Contingencies
- Compliance Period: The Company has until January 6, 2025 (180 days) to regain compliance.
- Compliance Criteria: To regain compliance, the closing bid price must be at least $1.00 for a minimum of 10 consecutive business days during the 180-day period.
- Secondary Compliance Period: If the Company fails to regain compliance within the initial 180 days, it may be eligible for an additional 180 calendar days, provided it meets all other initial listing standards (except the bid price rule) and intends to cure the deficiency, potentially through a reverse stock split.
- Risk: Failure to regain compliance within the allowed periods could result in delisting from Nasdaq.
Key Facts for Investor Verification
- Verify the current trading price of ABVC stock to assess proximity to the $1.00 threshold.
- Monitor the Company's announcements regarding any plans to effect a reverse stock split.
- Check for subsequent filings confirming whether the Company has achieved 10 consecutive days of trading above $1.00.
- Review the Company's latest 10-K or 10-Q for financial health, as this 8-K contains no financial data.